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Abstract
Summary We developed and validated a specific 12-item
questionnaire to evaluate adherence to oral antiresorptive
medication by post-menopausal osteoporotic women in
everyday practice. Over the following 9 months, an index
of ≤16 was associated with an increase in the risk of
treatment discontinuation of 1.69 and of 2.10 for new
patients who had started treatment within the previous year.
Introduction Adherence to medication in osteoporosis is
poor. The goal of this study was to develop and validate a
disease-specific questionnaire to evaluate adherence to
treatment of women with post-menopausal osteoporosis
taking oral antiresorptive medication.
Methods A prototype adherence questionnaire with 45
items developed from patient interview, literature review,
and physician opinion was evaluated in a sample of 350
post-menopausal women with osteoporosis treated in
primary care. Item responses were matched against scores
on the Morisky Medication Adherence Scale (MMAS). The
most discriminant items were retained in the final ques-
tionnaire. Concurrent and predictive validity were assessed.
Results Twelve items were associated with MMAS score at a
probability level of 0.05. These were retained in the final
questionnairewhichprovidedanadherenceindexrangingfrom
0 to 22. An indexof ≥20was associated with a high probability
of persistence and an index≤16 with a high probability of
treatment discontinuation in the following 9 months.
Conclusions The ADEOS-12 is a simple patient-reported
measure to determine adherence to osteoporosis treatments
with good concurrent and discriminant validity. This is the
first disease-specific adherence measure to have been
developed for osteoporosis.
Keywords Adherence.Compliance.Patient-related
outcomes.Persistence.Post-menopausal osteoporosis.
Questionnaire
Introduction
Osteoporosis is a bone disorder characterised by low bone
density associated with a deterioration in bone quality
(architecture, turnover, damage accumulation, and mineral-
ization) resulting in an increase in bone fragility [1]. This
leads to an increase in the risk of fractures, particularly of
the hip and vertebrae, which is associated with elevated
morbidity and mortality [2–4]. Osteoporosis affects one
woman in three after menopause [5] and is recognised by
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Osteoporosis can be effectively treated by therapies that
promote bone consolidation or prevent bone resorption,
such as the bisphosphonates [6], selective oestrogen
receptor modulators (SERMs) [7], strontium ranelate [8],
and teriparatide [9]. In randomised clinical trials, these
treatments can reduce fracture incidence by up to 50%.
However, in routine care, these treatment benefits may be
compromised by poor adherence to treatment, with around
50% of women discontinuing treatment within 1 year [10,
11]. Suboptimal adherence to antiresorptive treatment has
been shown to be associated with an increased risk of
fracture [12–14]. Barriers to better adherence to osteoporo-
sis treatment include the constraints associated with the
administration of some of these agents, side-effects, the
treatment regimen, the lack of a visible “read-out” of
treatment benefit and inappropriate patient expectations and
perceptions [15–17].
Improving adherence to osteoporosis treatment thus
represents an important public health issue. Achieving this
requires appropriate tools to measure adherence which can
be used to monitor improvements due to public health
interventions. The notion of adherence involves a number
of inter-related aspects. With regard to osteoporosis, an
expert consensus recently described adherence as a general
term encompassing both compliance and persistence [18].
Compliance was defined as the extent to which a patient acts
in accordance with the prescribed interval and dose of a given
treatment regimen, whereas persistence was defined as the
cumulative time from initiation to discontinuation of therapy.
Currently, three principal types of adherence measure have
been developed, prescription follow-up or pharmacy claims to
determine medication consumption over time, direct medica-
tion use measures (for example, pill counts, electronic
measures or canister weights) or patient reports. Direct
medication use measures are not particularly useful for
naturalistic studies, since they may lead to bias due to potential
modification of adherence behaviourby implementation ofthe
reporting measure. Of the prescription follow-up methods, the
medication possession ratio (MPR) [19, 20] has been widely
used. A number of patient-reported measures of treatment
adherence have been developed and validated, including the
Morisky Medication Adherence Scale (MMAS) [21], the
Medication Adherence Report Scale [22], the Adherence to
Refills and Medications Scale [23], the ASK-20 [24] and the
Hypertension Compliance Questionnaire [25]. However,none
of these instruments were designed specifically with osteopo-
rosisinmind,anditwouldthereforebeofinteresttodevelopa
disease-specific adherence measure which would focus on
adherence issues that are pertinent to osteoporosis and its
treatment and may be more discriminating and sensitive to
change than non-specific measures.
The primary objective of this study was to develop and
validateadisease-specificquestionnairetoevaluateadherence
to treatment of women with post-menopausal osteoporosis
takingoralantiresorptivemedication.Thesecondaryobjective
was to estimate the ability of this questionnaire to predict
treatment discontinuation or persistence.
Methods
The study was performed in France during 2008. The
questionnaire was developed in a population of women with
post-menopausal osteoporosis consulting a primary care physi-
cian and treated for osteoporosis in the previous 6 months. The
study includes a cross-sectional phase and a prospective phase.
Inthecross-sectionalphase,datawascollectedatthestudyvisit,
both from a questionnaire provided to the patient and from
patient records. In the prospective phase, prescription data were
collected over the 9 months following the index consultation.
Ethics
The survey protocol was submitted for evaluation to the
CCTIRS (National Ethics Advisory Board). They considered
that participation of patients in the study would not affect their
medical care and therefore it was not necessarytoobtain formal
Ethics Committee approval or to collect signed informed
consent from each patient. The only requirement stipulated was
that formal information on the goals and methods of the study
be provided for each patient. Analyses performed using the
Thalès database have been approved by the Commission
N a t i o n a l ed eL ’informatique et des Libertés (CNIL).
Participating physicians
The study was performed through the participation of 286
general practitioners (GPs) belonging to the Thalès net-
work. This is a computerised network of 1,200 GPs who
contribute exhaustive anonymous data on patient consulta-
tions and treatment to a centralised electronic database,
allowing subsequent follow-up of outcomes. GPs partici-
pating in the Thalès network are selected to be represen-
tative of the French GP population according to three main
criteria, namely geographical area, age, and gender.
Activity and prescription habits of the panel have also been
compared a posteriori with national data and shown to be
representative [26]. The database currently includes records
for >1.6 million patients, routinely collected since 2002. The
Thalès database has been demonstrated to be a reliable source
of information in numerous previous studies in rheumatology
[26–28] and in other fields of medicine [29–32].
For each patient, information on disease status and
medication prescription is entered directly into the database
446 Osteoporos Int (2012) 23:445–455by the physician at the time of the consultation. No
information as tothe reasons for makingindividual diagnostic
or prescription choices is however provided. The disease
status is encoded using terms from a specific thesaurus of
symptoms and disease entities adapted from the International
Classification of Diseases (ICD-10) system. Prescription data
contain the dispensed drug name (commercial and interna-
tional common denomination), the Anatomical Therapeutic
Chemical (ATC) classification category, dose regimens and
prescription duration.
Patients
Women aged 50 years or older were eligible for the study if
theyhadbeenprescribedaspecificoralosteoporosistreatment
(namely, bisphosphonates, SERMs or strontium ranelate)
within the 6 months preceding the start of the study. Patients
were required to have sufficient cognitive and linguistic
abilities, in the opinion of their GP, to complete the study
questionnaires ontheir own, and toprovide informed consent.
Women participating in clinical trials and those receiving an
injectable osteoporosis treatment (intravenous bisphospho-
nates and teriparatide) were excluded, as well as patients with
severe or progressive diseases for whom the physician
considered participation inappropriate.
Data collection
Two types of data were collected during the study. Cross-
sectional data were collected at the time of the study and
retrospective data were derived from the Thalès data. At the
time of the study visit, the patients were handed an ADEOS
questionnaire and an MMAS questionnaire to be completed
on their own and returned to the study centre. Physicians
completed an on-line Web-based case report form collecting
data on patient demographics, clinical history and current
treatment (medication type, dose, frequency of administra-
tion). The physicians also rated whether they considered each
patient to be adherent to treatment or not, using a six-point
Likert scale (all of the time, most of the time, from time to
time, rarely, never or no idea). Retrospective data retrieved
from the Thalès database provided information on treatment
history and were used to calculate the MPR. Information was
also collected on the age, gender and size of practice of
participating GPs to allow comparison with national norms.
Development of the ADEOS questionnaire
The ADEOS (ADherence Evaluation of OSteoporosis
treatment) questionnaire was developed to determine
adhesion to osteoporosis treatments. A Scientific Expert
Committee was involved with the development of the
questionnaire and was consulted between each stage of the
development process to ensure the credibility and perti-
nence of the proposed next steps. The development of the
questionnaire followed the following steps.
Thefirststepwasanexploratoryphaseaimedatidentifying
themespotentiallyimportanttoincludeinthequestionnaire.A
review of the scientific literature allowed existing instruments
for the evaluation of adherence or persistence with osteopo-
rosis treatment to be identified, as well as other relevant
concepts that may be interesting to include in the question-
naire. In parallel, a series of face-to-face semi-directive
interviews were conducted by an experienced clinical psy-
chologist with ten patientswithpost-menopausal osteoporosis
and experience of treatment, who were proposed by two GPs
and a rheumatologist. The aim of these interviews was to
collect information on these patients’ experience of their
osteoporosisand its treatment, toidentify barriersand benefits
associated with the use of these treatments, and to capture the
language used to describe these perceptions.
In a second step, the information collected from the
literature review and the patient interviews was used to
generate items for a draft questionnaire. This draft question-
naire was tested for comprehension by a panel of five patients
currently treated for post-menopausal osteoporosis. The goal
of this step was to verify that the selected items were
considered understandable and pertinent by the patients and,
ifthiswasnot thecase, togathersuggestions fromthe patients
on how these items could be reformulated (Table 1).
In a third step, a pilot study was implemented with 11
GPs who each recruited three patients treated for osteopo-
rosis. The aim of this pilot study was to evaluate the
acceptability of the questionnaire by its target population
(patients with osteoporosis) and by potential users (GPs) in
terms of relevance, ease of use, applicability and usefulness
for assessing adherence [33].
The prototype version of the questionnaire retained after
the pilot study was composed of 45 items relating to four
general concepts, namely beliefs, perceptions, behaviours
and information, as well as general patient data such as age
and time since diagnosis (see Table 2). Each item was
scored either by a dichotomous Yes/No response or on a
three-point Likert scale.
Other adherence measures
The study also assessed medication adherence using two other
non-specific adherence measures that had been validated
previously, the MPR [20]a n dt h eM M A S[ 21]. The MPR is
defined as the ratio between the length of time for which a
patient is in possession of prescribed medication and the time
since the first prescription. The MPR was determined from
data on all medication prescribed since 2002 (first availability
of the Thalès database). Since patients whose treatment was
initiated within the 3 months preceding the study visit would
Osteoporos Int (2012) 23:445–455 447have an MPR of 100% de facto (3 months is usually the
duration of a single prescription fill in France), these patients
were excluded from the analysis. Consistent with previous
studies of the MPR in patients with osteoporosis [10, 15, 34],
we considered patients with an MPR above 0.80 to be
adherent. In addition, a cut-off of 0.68 was also considered,
since this threshold has been demonstrated to be the most
sensitive for predicting elevated fracture risk in poorly
compliant patients [35].
The MMAS [21] is a self-administered rating scale that
contains four items relating to medication use behaviour.
Each item can be scored ‘yes’ or ‘no’, negative replies
being attributed a value of 1 and affirmative replies a value
of 0. A high score is associated with good adherence and a
score of less than 4 is considered to indicate inadequate
adherence. This scale was initially developed with eight
items for evaluating adherence to antihypertensive medica-
tion, but the four-item short form used in our study is now a
generic scale that has been applied to many types of
medication.
In addition, we also collected information on the
physician’s appreciation of their patient’s adherence. They
were asked whether they thought that their patient was
adherent all of the time, most of the time, from time to time,
rarely or never, or whether they had no idea. The purpose of
this question was to investigate how well the physician
could judge their patient’s adherence without the use of a
specific tool.
Finalisation of the ADEOS questionnaire and definition
of an adherence index
For this purpose, the ADEOS study population was divided
randomly into two independent data sets. The first set
(modelling set) was used to generate the structure of the
ADEOS score distribution and the second (validation set) to
valid this structure independently. The first 200 randomly
selected patients were assigned to the modelling set and the
remaining 148 to the validation set. In a first step, the
modelling set was used to select those items whose scores
were most closely correlated with an independent measure
of adherence, the MMAS score. All items associated with
the MMAS score were retained in the final questionnaire.
From the items retained, an adherence index was derived
by adding the scores of the individual items, having
standardised the direction of the response modality so that
the highest individual item score always corresponded to
the greatest adherence. The score was then tested in the
validation set by describing its ability to discriminate
between adherent and non-adherent patients assigned by
the MMAS score (MMAS score=4 and MMAS score <4,
respectively). Finally, relationships were evaluated between
the score and the MPR and between the score and the
physician’s judgement of patient adherence in the total
ADEOS study population.
Prediction of treatment discontinuation
Patient persistence was assessed 9 months after ADEOS
completion using prescriptions made to the patients. On
Table 1 Characteristics of the ADEOS population
N=350
Age (years) 70.9±8.8
<65 years 98 (28.0%)
65–75 years 118 (33.7%)
>75 years 134 (38.3%)
Marital status
Living alone 141 (40.3%)
Living with spouse or family 205 (58.6%)
Other 4 (1.1%)
Educational level
Primary school 70 (20.0%)
College 152 (43.4%)
High school 70 (20.0%)
University 58 (16.6%)
Employment status
In work 39 (11.1%)
Retired 301 (86.0%)
Out of work 10 (2.9%)
BMI (kg/m
2) 25.0±5.6
Previous fracture history 112 (32.0%)
Time since diagnosis (years) 5.3±4.7
Bone densitometry examination 310 (88.6%)
Treatment
Bisphosphonate 258 (73.7%)
SERM 58 (16.6%)
Strontium ranelate 34 (9.7%)
Daily 106 (30.0%)
Weekly 179 (51.1%)
Monthly 65 (18.6%)
MPR for all treatments
Mean ± SD 82.9%±18.7%
Adherent patient (MPR >80%) 220 (62.9%)
Adherent patient (MPR >68%) 270 (77.1%)
Physician judgement about patient adherence
All of the time 273 (78.0%)
Most of the time 67 (19.1%)
From time to time 8 (2.3%)
Rarely 1 (0.3%)
Never –
No idea 1 (0.3%)
Quantitative variables are presented as mean values ± standard
deviations and categorical variables as absolute patient numbers (%)
ADEOS adherence and osteoporosis questionnaire, BMI body mass
index, MPR medication possession ratio, SD standard deviation,
SERM selective oestrogen receptor modulator
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period, patients were divided into a “discontinued” group
and a “persistent” group. The ability of the ADEOS
index to predict discontinuation was evaluated by
calculating the relative risks of treatment discontinuation
of patients by ADEOS category. The analysis was
replicated in the subgroup of patients with recent
treatment initiation (<1 year). Other potential predictors
of discontinuation were also investigated using univariate
logistic regressions: age, professional status, level of
education, fracture history, polymedication, length of
diagnosis, and treatment duration (more than 6 months
vs. less than 6 months).
Statistical analysis
Two study populations were considered in the analysis, a
total study population, and an ADEOS study population.
The total study population corresponded to all patients
included in the study. The ADEOS study population was
arbitrarily defined as all patients who had returned an
exploitable ADEOS questionnaire with at least 23 (i.e. half)
of the 45 items completed. Missing data were not replaced,
and these were taken into account for the calculation of
percentages.
Categorical variables were compared with the χ
2 test
or Fisher’s exact test, as appropriate. Quantitative varia-
bles were compared using Student’s t test or analysis of
variance (ANOVA) if these were normally distributed,
otherwise with the Mann–Whitney-Wilcoxon test or the
Kruskall–Wallis test as appropriate. In order to generate
the final questionnaire, all items in the 45-item question-
naire were tested for their association with adherence
measured with the MMAS score. Those items showing a
significant association at a probability value of 0.05
(Mann–Whitney U test for dichotomous variables and
Kruskall–Wallis test for Likert scales) were retained in the
final questionnaire. The performance of the adherence
index to discriminate between two patient groups was
tested in the validation set using Receiver-Operating
Characteristic (ROC) curves.
Datawerecontrolled, validated and analysedcentrally. The
analyses were performed using SAS® software version 9.1.3
for Windows (SAS Institute, Cary, NC, USA).
Table 2 Concepts and items retained in the ADEOS-12 score
General concepts Content Items retained in the ADEOS-12 score
Beliefs (12 source items) Osteoporosis consequences; osteoporosis acceptance;
about osteoporosis treatment (curative, preventive,
important for health, important compared with
other treatments); instructions to follow: important,
easy; feeling reassured and protected by the
treatment; importance of the BMD test
Item 29, “My osteoporosis medication is
important to my health.”
Item 24, What motivates you to take your
osteoporosis medication?
Item 25, How motivated are you to keep
taking your osteoporosis medication?
Perceptions (ten source items) Level of bone fragility; inability to notice osteoporosis
evolution; concern about osteoporosis diagnosis;
concerns (falls, fractures, disability); treatment
constraints; easy to take treatment; treatment efficacy;
inability to notice treatment beneficial effects;
treatment side-effects
Item 16, Do you feel that your osteoporosis
medication is easy to take?
Item 18, Are the instructions for taking your
osteoporosis medication inconvenient for you?
Behaviour (13 source items) Forgetting/skipping treatment; tricks for remembering
treatment; involvement of patient (for BMD test,
in decision-making, consulting regularly, seeking
information); daily life adaptation to osteoporosis;
daily life adaptation to treatment; motivations to
take treatment; intention to continue treatment
Item 21, Do you ever forget to take your
osteoporosis medication?
Item 22, Do you ever skip your medication
because of unexpected circumstances?
Item 23, How do you remind yourself to
take your osteoporosis medication?
Item 30, “I have become used to taking my
osteoporosis medication.”
Item 31, “I make sure to carefully follow the
instructions I’m given about taking my
osteoporosis medication.”
Information (three source items) Need more information/explanation about osteoporosis
or treatment; information from friends or relations;
consistency of information
Item 17, Did you receive specific instructions
on how to take your osteoporosis medication?
Item 32, “The instructions for taking my
osteoporosis medication are clear enough.”
Patient features (seven source items) Age; diagnosis of osteoporosis; family history of
osteoporosis; fracture history; history of BMD
testing; treatment; reimbursement
None retained
The wordings of the French and English version of the questionnaire, as well as the scoring system are provided in Appendix 1. ADEOS-12: 12-
item adherence and osteoporosis questionnaire
BMD bone mass densitometry
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Study sample
A total of 560 patients were included in the study by 228
GPs. For these patients, Web-based case report forms were
completed on-line and this thus constituted the total study
population and the physician population. All patients were
provided with ADEOS and MMAS questionnaires to
complete and return. ADEOS questionnaires were returned
by 350 patients (62.5%), and these were exploitable for 348
patients who constituted the ADEOS study population. The
ADEOS study population was divided into a modelling set
(N=200) and a validation set (N=148).
The completion rate of the questionnaire was acceptable,
with 194 patients (55.7%) filling in the entire questionnaire
and 327 (93.4%) completing at least 42 of the 45 proposed
items. The mean number of missing items was 1.2±3.1.
Two items accounted for completion failure in over 30% of
patients. These items were not retained in the final
questionnaire. Only two patients failed to complete more
than half of the 45 items of the prototype questionnaire and
were considered unexploitable.
Patient characteristics
The characteristics of patients returning their ADEOS question-
naires are presented in Table 1. The mean age of the sample
was 71.2±8.9 years and 34.8% had previously experienced a
fracture. The mean time since diagnosis of osteoporosis was
5.4±4.7 years and 87.3% had undergone bone densitometry.
The most commonly prescribed treatments for osteoporosis
were bisphosphonates (in 75.7% of patients) and a little over
half were prescribed a treatment to be taken weekly (52.9%).
No difference between patients returning their ADEOS
questionnaires and those who did not return them was
observed for any of these variables (data not shown).
Measures of adherence
Previous adherence to osteoporosis treatment was deter-
mined using the MPR for the entire treatment period. Mean
MPR values and the proportion of adherent patients using
cut-offs of 0.80 and 0.68 are presented in Table 1. There
was no difference in MPR values between the patients
returning their ADEOS questionnaires and those not
returning them for any of the MPR variables studies, with
the exception of the proportion of patients adherent over
their entire treatment period using a threshold of 0.80,
which was higher in patients returning their questionnaire
(p=0.021).
According to the judgement of the GP as to whether
their patients were adherent to treatment or not, 97.1% of
patients were considered to be adherent all or most of the
time (Table 1), again with no significant difference between
patients returning or not returning their questionnaires (data
not shown). For patients returning an MMAS questionnaire,
the mean MMAS score was 3.5±0.8. The distribution of
MMAS score is presented in Fig. 1, with 62.9% of
respondents scoring 4 on this rating scale and thus being
considered as adherent.
Adherence measured by the MMAS was significantly
associated with the physician’s judgement of patient
adherence (p=0.0001). However, the correlation between
the MMAS and the MPR for the most recent treatment was
limited (r
2=0.1195; p=0.034), and there was no association
between MPR and the physicians judgement (p=0.749).
Item selection and scoring
Overall, 12 items were associated with the MMAS score at a
probability thresholdof≤0.05.These are listed in Table2.W i t h
the exception of Item 23 (19 patients did not reply to this
question), data were missing for less than 5% of patients for
the selected items (one to ten patients according to the item).
The scoring system is described in the questionnaire
provided in Appendix 1. Three types of question were
retained in the questionnaire (Table 3). The first type of
question (for example, Q9 in Table 3) related to factors that
were associated with high MMAS scores and were scored
on a three-point Likert scale, with +2 being attributed to the
most favourable response, +1 to the intermediate response
and 0 to the least favourable response. In a similar fashion,
the second type of question related to factors associated
Fig. 1 Distribution of MMAS
(left) and ADEOS-12 (right)
scores. Data are presented as
absolute numbers of patients.
ADEOS-12: 12-item adherence
and osteoporosis questionnaire;
MMAS Morisky Medication
Adherence Scale
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were scored −2, −1 or 0. The third category of question
were multiple response questions (for example Q6), in
which responses associated with high MMAS scores were
attributed +1 and those associated with low MMAS scores
−1. The sum of the scores for each item was calculated and
8 added to this sum in order to avoid potential negative
values. This number represented the final ADEOS-12 score,
which could take values ranging from 0 (lowest adherence)
to 22 (highest adherence).
The distribution of the ADEOS-12 score in the ADEOS
study population is illustrated in Fig. 1. The mean ± SD and
median value of the score were 18.7±2.8 and 19,
respectively. The vast majority of patients (percent)
presented a score in the upper half of possible scores
(>11). No differences in mean ADEOS-12 score or in its
distribution, as a function of age group, marital status,
educational status, type or frequency of administration of
osteoporosis treatment, duration of treatment or use of other
medication (data not shown). However, the score was slightly,
but significantly (p=0.048) higher in patients without a history
of fracture than in those with such a history.
Psychometric validation of the ADEOS-12
The psychometric validation of the ADEOS-12 question-
naire was performed in the 148 patients in the validation
set. The score was moderately correlated with the MMAS
score in this population (r
2=0.58; p<0.0001). The ADEOS-
12 showed high discriminatory power with respect to
adherence measured with the MMAS, as demonstrated by
an estimated area under the ROC curve of 0.842 (Fig. 2).
Concurrent validation of the ADEOS-12
With respect to adherence measured with the MPR, the
discriminatory power of the ADEOS-12 was quite low, with
estimated areas under the ROC curve ranging from 0.63 [95%
confidence limits, 0.52 to 0.76] to 0.67 [0.53 to 0.81],
accordingtotheMPR definitionused. The correlationbetween
the ADEOS-12 score and the MPR was low but nonetheless
significant (Spearman rank coefficient, 0.12; p<0.03). With
respect to the physician’s judgement, the mean ADEOS-12
score was also significantly higher (p<0.0001; Student’s t
test) in patients who were considered to be adherent all of the
time (score=19.1±2.4) compared with those who were
considered not to be always adherent (17.1±3.5).
Table 3 Examples of questions and response modalities in the
ADEOS-12 questionnaire
Q9. My osteoporosis medication is important to my health
□ Yes, completely +2
□ Somewhat +1
□ No, not at all 0
Q4. Do you ever forget to take your osteoporosis medication?
□ Never 0
□ Sometimes −1
□ Often −2
Q6. How do you remind yourself to take your osteoporosis medication
□ The people around me remind me 0
□ I have a way to remind myself 0
□ It has become natural to me +1
□ Other (specify)0
□ I don’t know what to do to remember −1
ADEOS-12: 12-item adherence and osteoporosis questionnaire
BMD bone mass densitometry
Note: For routine practice, item’s scores can be replace with stars
(positive figures) and circles (negative figures) (cf. Appendix 1)
Fig. 2 Receiver-Operating Characteristics curve for the ability of the
ADEOS-12 score to discriminate between adherent (MMAS score=4)
and non-adherent (MMAS score <4) defined by the MMAS (Morisky
Medication Adherence Scale). ADEOS-12: 12-item adherence and
osteoporosis questionnaire
Fig. 3 Sensitivity (closed square) and specificity (closed circle)o ft h e
ADEOS-12 Adherence Index at discriminating adherent and non-adherent
patients defined with the MMAS (Morisky Medication Adherence Scale).
ADEOS-12: 12-item adherence and osteoporosis questionnaire
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index
The specificity and sensitivity of different score thresholds for
detecting patients with an MMAS score of 4 (optimal
adherence), and those with a lower score was also evaluated
in the total ADEOS population (Fig. 3). Three groups of
patients could be distinguished, those with a score≥20 (the
“shoulder” on the specificity curve), those with a score≤16
(the “shoulder” on the sensitivity curve) and those with a score
of 17 to 19. In the former group, 87.6% presented an MMAS
score of 4 and were thus adherent. For the patients with a score
≤16, 81.4% were sub-optimally adherent (MMAS score<4).
Predictive validity
During the 9 months following the index consultation, all
patients returned to consult their GP at least once, irrespective
of the reason. Of these, 226 patients (64.9%) had been
persistent and 122 (35.1%) had discontinued their treatment.
The ADEOS score at baseline significantly predicted treat-
ment discontinuation over the following 9-month period (p=
0.005). Compared with patients with good adherence to
treatment (ADEOS score≥20), patients with ADEOS-12
scores between 16 and 19 had a 1.36 times higher risk and
those with scores≤16 a 1.69 times higher risk of treatment
discontinuation before 9 months (Table 4). Considering the
119 patients whose treatment had been initiated in the
previous year, 68 (57.1%) were persistent and 51 (42.9%)
had discontinued. In this group, the relative risks of treatment
discontinuation were respectively 1.43 and 2.10. No other
variable tested was significantly associated with treatment
discontinuation at a probability threshold of 0.05.
Discussion
This study was performed to develop and validate a disease-
specific, patient-reported measure to evaluate treatment
adherence in patients treated chronically for osteoporosis.
An extensive 45-item prototype questionnaire was reduced to
a 12-item questionnaire by selection of items most strongly
associated with self-reported adherence determined with the
MMAS. In an independent validation sample of women
treated for osteoporosis, the ADEOS-12 questionnaire
showed satisfactory concurrent and discriminant validity.
The adherence score also demonstrated a good ability to
predict treatment discontinuation over the medium term and
particularly in patients with a short treatment history.
The ADEOS-12 score was moderately correlated with the
MMAS score (r
2=0.58) and discriminated well between
patients considered as optimally adherent (MMAS score=4)
and sub-optimally adherent (MMAS score<4). Indeed, the
area under the ROC curve was 0.842, demonstrating high
specificity and sensitivity. Since the MMAS was used as the
criterion to retain items in the ADEOS-12, some correlation is
expected as a direct consequence of how the items were
selected. However, the correlation may be imperfect, since
the ADEOS-12 covers, in addition, attributes of adherence
other than those covered by the MMAS. Unlike, the latter, the
ADEOS-12 is a specific questionnaire for women treated for
osteoporosis and thus may represent a more global measure
of adherence in this disease. The proportion of sub-optimally
adherent patients determined with the MMAS was 37.1%,
which is comparable with the rate of 34.5%, reported recently
in a larger survey of post-menopausal women with osteopo-
rosis in France [36].
Furthermore, the ADEOS-12 score also discriminated
between patients considered to be always adherent and not
always adherent by their physician. In contrast, the
ADEOS-12 was poorly, albeit significantly, correlated with
the MPR, which reflects the fact that the two instruments do
not measure the same thing. Whereas the MPR is an
objective measure of expected drug intake (medical
prescription/pharmacy retail), the ADEOS score assesses
subjective beliefs, perceptions, behaviour and information
with regard to treatment. The finding is consistent with
many previous studies which have shown that adherence
measured by self-report is poorly correlated with measures
based on prescription rates or medication use [37–41].
Consistent with this, the relationship between the MPR and
the MMAS score in our study was weak, and the MPR was
Persistent Discontinued Relative risk
All patients
ADEOS-12 score≥20 103 (71.0%) 42 (29.0%) 1
ADEOS-12 score 17–19 74 (60.7%) 48 (39.3%) 1.36 [0.97–1.90]
ADEOS-12 score≤16 22 (51.2%) 21 (48.8%) 1.69 [1.13–2.51]
Patients starting treatment within previous year
ADEOS-12 score≥20 30 (68.2%) 14 (31.8%) 1
ADEOS-12 score 17–19 24 (54.5%) 20 (45.4%) 1.43 [0.83–2.45]
ADEOS-12 score≤16 6 (33.3%) 12 (66.7%) 2.10 [1.22–3.60]
Table 4 Persistence rates over
the 9 months following consul-
tation as a function of ADEOS-
12 score at the index
consultation
Relative risk rates are provided
with their 95% confidence
intervals. ADEOS-12: 12-item
adherence and osteoporosis
questionnaire
452 Osteoporos Int (2012) 23:445–455not significantly related to the physician’s judgement of
adherence. Since the ADEOS-12 was developed with
benchmarking to the MMAS, it is not surprising that it is
correlated with the latter rather than with the MPR. With
respect to prospective collection of data on adherence,
however, the ADEOS-12 score did perform well in predict-
ing treatment discontinuation, especially in recently treated
women who are less likely to be persistent. Physician
judgement was of patient adherence seemed overly optimis-
tic, since they considered 97% of patients to be adherent all
or most of the time. As indicated in previous studies,
physician judgement of adherence was poorly correlated
with patient-reported measures of adherence. This highlights
theinterest of asimpletool for physicians touse todetermine
patient adherence, rather than relying uniquely on their own
judgement.
The ADEOS-12 presents a number of advantages for the
evaluation of treatment adherence in women with osteoporosis.
Firstly, it provides a disease-specific measure which captures
information on treatment and patient attributes which are
pertinent to the disease and which may provide clues to
improving adherence. For example, if non-adherent patients
consistently report that recommendations for taking their
medication are unclear or difficult to follow (items 18 and 32
of the ADEOS), then this would be an incentive to reformulate
the recommendations. Although disease-specific adherence
questionnaires have been developed in a few disease areas
[42–44]; up to now, no such instrument has been made
available for the study of osteoporosis. Secondly, the ques-
tionnaire is short and simple to use (12 items with either two or
three potential response modalities) and seems understandable
and acceptable to patients since the amount of missing data on
returned questionnaires was limited (only two patients
completed less than half the items). The scoring is simple
and rapid for the rater to perform. Thirdly, compared with the
MMAS, the ADEOS-12 has a richer content, covering
multiple aspects of medication use, including perceptions of
disease, perceptions of treatment and attitudes to taking
medication. Moreover, the score, which ranges over 22 points,
offers a more highly resolved estimate of adherence than the
four-point MMAS score, whereby different degrees of
suboptimal adherence can be identified. In particular, it
appeared that the ADEOS-12 index showed a notably less
important ceiling effect than the MMAS score, indicating that
it may be more able to identify slight deviations from perfect
behaviour. Fourthly, the ADEOS-12 score seems to be
relatively independent of sociodemographic, clinical and
treatment variables, although numerically small, albeit signif-
icant, differences were observed for fracture history and
treatment duration. This suggests that the ADEOS-12 can
providecomparable data from different patientgroups andthat
it is sensitive to psychological variables that may underlie
individual differences in adherence, such as treatment expect-
ations,disease perceptions, attitudes to risk, mood and patient–
physician relationships [45]. Next, the ADEOS-12 provides
complementary information to other measures of adherence.
It clearly measures a different dimension of adherence to the
MPR, with which it is poorly correlated, but also is
complementary to the MMAS, providing additional informa-
tion on patient perceptions, as indicated by the only moderate
correlation between the MMAS score and the ADEOS-12
score. In addition, this disease-specific index is complemen-
tary to general adherences measures, which are useful to
compare adherence across different diseases, but are often
relatively insensitive. Finally, psychometric analyses identi-
fied two pragmatic score thresholds (16 and 20) which
provide a good basis to guide interpretation of the score in
daily practice. A patient with an ADEOS index≥20 is
expected to be unlikely to discontinue while a patient with
an index≥16 is at risk for treatment discontinuation. Given
that many of the attributes of medication adherence, for
example patient–physician relationships and patient empow-
erment, are likely to be culturally dependent, it will be
important to validate the psychometric properties of the
ADEOS-12 questionnaire and its score thresholds in other
countries. To this end, a validated translation of the ADEOS-
12 questionnaire into English is provided in the Appendix.
Our study has certain limitations. Firstly, the response rate
was only moderate, with 62.5% of patients returning a
completed ADEOS questionnaire. In order to limit potential
social pressure on patients to “conform” [46] and in order to
match as closely as possible naturalistic conditions of use of
the questionnaire, no attempts were made to contact patients
who had not returned their questionnaires spontaneously to
remind them to do so. However, even if non-adherent
patients are under-represented in our sample, they still make
up a significant proportion of the sample, with 26% having
an MPR <0.80 for their most recent treatment and 35%
scoring less than four on the MMAS. Another potential
source of non-representativity relates to patients who did not
return to see their GP after the initial prescription of
osteoporosis treatment, who were not accessible for the
study. These patients are likely to be non-persistent and the
adherence rates estimated in our study may in consequence
be somewhat over-estimated. Another limitation is that
women receiving injectable antiresorptive treatments were
excluded from the study, since it was considered that their
adherence behaviour would be governed by quite different
principles. The validity and performance of the ADEOS
questionnaire in other populations, such as women receiving
injectable treatments, remain to be confirmed.
In conclusion, the ADEOS-12 provides the physician with
a simple patient-reported measure to determine adherence to
osteoporosis treatments. This is the first disease-specific
adherence measure to have been developed for osteoporosis,
a disease in which poor treatment adherence is a major issue.
Osteoporos Int (2012) 23:445–455 453The questionnaire has good concurrent and discriminant
validity; its items are relevant and meaningful to the target
population and may provide useful information on why
adherence is suboptimal. Its use may provide complementary
or more exhaustive information on adherence than currently
available non-specific adherence measures.
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